Trading Options with an Edge
Select Page

DVAX

Search by
TICKER SYMBOL

Dynavax Technologies Corp.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing

18.79

3.93

(26.447%)

Volume:

30,508,009

52 week range:

3.58 - 20.66

Market Cap:

2.156B

Company Description:

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.